NEUROENDOCRINE EFFECTS OF SUBCUTANEOUS INTERLEUKIN-2 INJECTION IN CANCER-PATIENTS

被引：18

作者：

LISSONI, P ^{[1
]}

BARNI, S ^{[1
]}

ROVELLI, F ^{[1
]}

CRISPINO, S ^{[1
]}

FUMAGALLI, G ^{[1
]}

PESCIA, S ^{[1
]}

VAGHI, M ^{[1
]}

CAMESASCA, G ^{[1
]}

TANCINI, G ^{[1
]}

机构：

[1] OSPED CARATE,DIV MED,CARATE,ITALY

来源：

TUMORI | 1991年 / 77卷 / 03期

关键词：

D O I：

10.1177/030089169107700305

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Intravenous interleukin-2 (IL-2) administration has been shown to influence several hormonal secretions. The present study was carried out to investigate the endocrine effects of subcutaneous therapy with IL-2. Six patients with advanced renal cancer were studied. They were treated subcutaneously with IL-2 according to the schedule proposed by Atzpodien et al. Venous blood samples were collected at O-time and 1, 8 and 12 hours after the first IL-2 pulse of 9 x 10(6) IU/m2 at 8.00 a.m.; on a separate occasion, samples were collected during a saline infusion only. In each blood sample, serum levels of cortisol, beta-endorphin, GH, PRL, FSH, LH, TSH and the pineal hormone melatonin were measured by RIA. Both cortisol and beta-endorphin significantly increased after IL-2 injection. GH rose but not to a significant extent. PRL, FSH, LH and TSH did not change after IL-2. Finally, melatonin levels markedly decreased after IL-2 injection in the only 2 patients with elevated concentrations of this hormone before the start of immunotherapy. These results suggest that the endocrine effects of subcutaneous IL-2 therapy are similar to those previously described with intravenous administration.

引用

页码：212 / 215

页数：4

共 12 条

[1] PHASE-I EVALUATION OF RECOMBINANT INTERLEUKIN-2 IN PATIENTS WITH ADVANCED MALIGNANT DISEASE [J].